HEPA Archives - Page 9 of 11

Developments

Hepion CRV431 to advance to Phase 2a trial for NASH fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) is planning to commence a Phase 2a trial of CRV431 for the treatment of NASH fibrosis in June. The study, called AMBITION, will enroll 18 adults with presumed NASH F2- or F3-stage...

May 19, 2020

Feature

Amidst a global pandemic, two biotech companies offer innovative solutions

Since COVID-19 was first identified in China late last year, researchers have been working tirelessly to develop diagnostics, therapeutics and vaccines in an effort to prevent the spread of the SARS-CoV-2 virus. Many...

March 31, 2020

Markets

Analysts see strong rationale for Hepion CRV431’s use in severe COVID-19 cases

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431, a cyclophilin inhibitor with antifibrotic and antiviral properties, may show some effect in the ongoing COVID-19 pandemic, according to Roth Capital Partners and Brookline...

March 20, 2020

Developments

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of CRV431 on lung tissue obtained from a patient with idiopathic pulmonary fibrosis (IPF). In the...

March 12, 2020

Developments

Hepion’s CRV431 shows potential to impact multiple types of fibrotic disease

Hepion Pharmaceuticals (NASDAQ:HEPA) reported results from in vitro studies showing that CRV431 can decrease production of the extracellular matrix (ECM) molecules, collagen and fibronectin, from fibroblastic cells. The...

February 19, 2020

Developments

Hepion advances to third dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the third dose level of CRV431 in its ongoing Phase 1 multiple ascending dose trial. The clinical trial management team determined the 150 mg dosing level to be safe and...

February 12, 2020

Markets

Roth sees Hepion completing transition into NASH company in 2020

Hepion Pharmaceuticals (NASDAQ:HEPA) is poised to make the final stages of its transition into a company focused on non-alcoholic steatohepatitis (NASH) in 2020 with two key catalysts that will show off the potentially...

January 29, 2020

Developments

Hepion reports positive results of CRV431 in expanded human liver study

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that its non-alcoholic steatohepatitis (NASH) candidate, CRV431, demonstrated superior antifibrotic efficacy in an expanded human liver study. The study design and its...

January 28, 2020

Developments

Hepion to present update on CRV431 nonclinical studies at NASH-TAG 2020 conference

Hepion Pharmaceuticals (NASDAQ:HEPA) is slated to present a poster at the upcoming NASH-TAG 2020 conference. The presentation will provide details of four nonclinical studies demonstrating that CRV431 decreases liver...

January 8, 2020

Developments

Hepion advances to next dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the next higher dose of CRV431 in its ongoing Phase 1 multiple ascending dose trial in healthy volunteers. The clinical trial management team determined the 75 mg dosing...

December 10, 2019

Tag - HEPA

Hepion CRV431 to advance to Phase 2a trial for NASH fibrosis

Amidst a global pandemic, two biotech companies offer innovative solutions

Analysts see strong rationale for Hepion CRV431’s use in severe COVID-19 cases

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Hepion’s CRV431 shows potential to impact multiple types of fibrotic disease

Hepion advances to third dosing level in ongoing Phase 1 study of CRV431

Roth sees Hepion completing transition into NASH company in 2020

Hepion reports positive results of CRV431 in expanded human liver study

Hepion to present update on CRV431 nonclinical studies at NASH-TAG 2020 conference

Hepion advances to next dosing level in ongoing Phase 1 study of CRV431

General

More